Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on developing and commercialising a proprietary therapeutic stem cell platform technology, Cymerus™. This platform utilises induced pluripotent stem cells (iPSCs) and a precursor cell, mesenchymoangioblast (MCA), to achieve scalable and consistent manufacturing of mesenchymal stem cells (MSCs). Cynata's technology aims to address the critical issues of scale, batch-to-batch consistency, and manufacturing costs that have historically hindered the broader adoption of MSC therapies. Their lead product candidate, CYP-001, has been investigated for treating steroid-resistant acute graft-versus-host disease (GvHD), and the company is exploring other therapeutic areas including osteoarthritis, critical limb ischemia, and respiratory distress.
Serves as the central hub for corporate administration, research and development oversight, clinical trial management, and strategic business development.
Located in a modern commercial building within a precinct known for innovation, providing a contemporary and collaborative workspace.
The work culture at Cynata's HQ is likely characterized by scientific rigor, innovation, collaboration, and a strong focus on achieving clinical milestones and advancing regenerative medicine.
The Melbourne headquarters places Cynata within Australia's prominent biomedical research ecosystem, facilitating access to talent, research institutions, and clinical trial sites.
While headquartered in Australia, Cynata Therapeutics maintains a global outlook for its clinical development and commercialisation strategies. They collaborate with international research institutions, contract manufacturing organizations (CMOs), and contract research organizations (CROs). Their clinical trials often involve sites in multiple countries, and they engage with regulatory authorities such as the FDA (USA) and EMA (Europe) for their product candidates. Strategic partnerships, like the one with Fujifilm for GvHD, extend their operational reach, particularly in markets like Japan.
Level 3, 100 Cubitt Street
Cremorne
Victoria
Australia
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Cynata Therapeutics' leadership includes:
Cynata Therapeutics has been backed by several prominent investors over the years, including:
Cynata Therapeutics has strengthened its executive team with a new COO and seen changes in Board leadership over the past year, positioning the company for further clinical and corporate development.
Discover the tools Cynata Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Cynata Therapeutics likely utilizes common corporate email formats. The most probable patterns are [first_initial][last]@cynata.com or [first].[last]@cynata.com.
flast@cynata.com (e.g., jdoe@cynata.com) or first.last@cynata.com (e.g. jane.doe@cynata.com)
Format
rmacdonald@cynata.com
Example
80%
Success rate
Proactive Investors • 2024-05-20
Cynata Therapeutics reported positive final data from its Phase 1 clinical trial of CYP-001 in patients with osteoarthritis (OA), showing safety and efficacy signals....more
Cynata Therapeutics ASX Announcement • 2024-03-26
Cynata Therapeutics announced it received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to proceed with its Phase 2 clinical trial of Cymerus™ MSCs in patients with diabetic foot ulcers (DFU)....more
Cynata Therapeutics ASX Announcement • 2023-12-04
Cynata Therapeutics announced the appointment of Dr. Darryl Maher as Non-Executive Chairman, effective immediately. Dr. Maher brings extensive experience in the biotechnology and pharmaceutical industries....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Cynata Therapeutics, are just a search away.